Anti-cancer drugs trade margins are capped at 30%, leading to significant price reductions for consumers.
Cancer drug prices may fall significantly, offering real savings for patients and healthcare systems.
Overseas pharmaceutical approvals are reshaping the industry, confirming profit recovery trends.